Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 730,000 | 5% |
| Gross Profit | 730,000 | 5% |
| Operating expense | 65M | 1.8% |
| Net Income | -57M | 5.2% |
| EBITDA | -63M | 1.8% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 692M | 6.4% |
| Total Liabilities | 37M | 1.4% |
| Total Equity | 655M | 6.8% |
| Shares Outstanding | 66M | 0% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -44M | 19.1% |
| Cash from investing | 50M | 16.1% |
| Cash from financing | 63,000 | 68.8% |
EPS
Financial Highlights for Celldex Therapeutics in Q2 '25
Celldex Therapeutics reported a revenue of 730,000, which is a 5% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 730,000, marking a 5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Operating Expenses for this period were 65M, showing a 1.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -57M, showing a -5.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -63M, showing a -1.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Celldex Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
